CELL & GENE CAPACITY UPDATE VIDEOS
FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Cell & Gene Therapy
Director of Commercial Development, Serat Ali, describes FDBs' Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.
Vinta Bio Capacity Update April 2025: Cell & Gene Therapy
Uncover how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.
Kincell Bio Capacity Update April 2025: Cell & Gene Therapy
Explore how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.
Capacity Update April 2025: Cell & Gene Therapy
Witness how NYBCe and CCS are transforming cell and gene therapy development with end-to-end CDMO solutions, advanced logistics, and a growing innovation hub in Louisville.
Miltenyi Biotec B.V. & Co. KG Capacity Update April 2025: Cell & Gene Therapy
In this presentation, Shaan Gareeb highlights the capabilities of our Cell Therapy Center of Excellence in San Jose, California, one of five global Miltenyi Bioindustry sites.
Andelyn Capacity Update April 2025: Cell & Gene Therapy
Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.
SK pharmteco Capacity Update April 2025: Cell & Gene Therapy
Our integrated expertise — from plasmid science to viral vector and cell therapy manufacturing — can accelerate and de-risk the development of your advanced therapies.
Advancing Cell & Gene Therapies To Patients
Discover how we apply our expertise and know-how to efficiently advance your viral vector-based therapeutic through any phase, while enhancing quality and de-risking production.
Forge Biologics, A Member Of Ajinomoto Bio-Pharma Services, Capacity Update January 2025: Cell & Gene Therapy
See how Forge’s dedicated 200,000 sq. ft. facility, proprietary technologies, and specialized services provide expert AAV manufacturing to empower developers from discovery to delivery and every step in between.
Andelyn Biosciences Capacity Update January 2025: Cell & Gene Therapy
Here we introduce the structure and capabilities of our Laboratory Services group, a cornerstone of our commitment to excellence in pharmaceutical development.
Aldevron Capacity Update January 2025: Cell & Gene Therapy
In this session, you will discover how Alchemy technology utilizes a cell-free, enzymatic DNA manufacturing process that accelerates linDNA template production, allowing you to expedite your mRNA research and development pipeline.
Theragent Capacity Update October 2024: Cell & Gene Therapy
Our Arcadia, CA facilities provide cell therapy development, testing, manufacturing, a proprietary digital trial platform, and preclinical research through our Discovery Center.
Viralgen Capacity Update October 2024: Cell & Gene Therapy
Advance your rAAV gene therapy from concept to commercial scale, leveraging our world-leading expertise and capacity to bring life-changing treatments to patients in need.
Minaris Advanced Therapies Capacity Update October 2024: Cell & Gene Therapy
An update on our Philadelphia campus: comprehensive CGT services, from discovery to clinical production, with integrated bioanalytical testing to streamline timelines and reduce risks.
ElevateBio Capacity Update October 2024: Cell & Gene Therapy
Katie Jorgensen introduces ElevateBio BaseCamp's path to commercial readiness in cell therapy, highlighting key strategies for scaling from clinical to commercial manufacturing, with a focus on staffing, training, and preparation for 2025.
Advanced Medicine Partners Capacity Update October 2024: Cell & Gene Therapy
Gain insight into our unparalleled expertise as a leading CDMO in viral vectors, offering top-tier process development, analytical development, and manufacturing solutions.
Andelyn Biosciences Capacity Update October 2024: Cell & Gene Therapy
Discover our innovative DOE-based strategy for developing a scalable suspension platform to produce and purify AAV vectors, optimizing consistency, productivity, and quality across scales.
FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Cell & Gene Therapy
Here, we showcase our investment in cell therapy services and explore the innovative designs and expansions at the Thousand Oaks facility that will enhance GMP production capabilities.
IDT Biologika Capacity Update October 2024: Cell & Gene Therapy
With over 30 years of GMP manufacturing expertise, we offer dedicated capacity for clinical and commercial gene therapy batches, using advanced AAV platforms and proprietary cell lines.
SK pharmteco Capacity Update October 2024: Cell & Gene Therapy
Check out our enhanced capacity and expertise in supporting CGT projects, offering end-to-end solutions from viral vector and plasmid development to GMP manufacturing and regulatory support.
Don't miss our next installment!
These conferences are ideal for professionals who have the authority to choose and manage CDMO relationships and need to secure capacity for their development or commercial programs.
How can we help?
Are you a supplier looking to present at our next event?